Stock Price
57.23
Daily Change
0.53 0.93%
Monthly
3.79%
Yearly
4.57%
Q4 Forecast
55.94

EPS Reference Time Actual Consensus Previous
2026-11-02 FY2026Q3 PM 0.23 1.49 0.12
2026-08-06 FY2026Q2 PM 1.20 0.95 1.44
2026-05-04 FY2026Q1 PM 0.76 0.74 1.13
2026-02-23 FY2025Q4 PM 0.46 0.77 0.92
2025-10-27 FY2025Q3 PM 0.12 0.86 0.91



Peers Price Chg Day Year Date
Acadia Pharmaceuticals 18.75 0.61 3.36% -21.94% Nov/13
Agios Pharmaceuticals 31.59 -0.17 -0.54% -27.63% Nov/13
Alnylam Pharmaceuticals 165.04 8.39 5.36% -63.26% Nov/13
Amgen 465.67 -1.39 -0.30% 38.29% Nov/13
Bayer 57.16 0.64 1.13% 104.54% Nov/16
Biogen 253.40 2.92 1.17% 51.24% Nov/13
BioMarin Pharmaceutical 57.23 0.53 0.93% 4.57% Nov/13
Gilead Sciences 168.08 0.13 0.08% 34.44% Nov/13
Incyte 120.97 -0.73 -0.60% 16.15% Nov/13
Insmed 121.16 3.09 2.62% -37.29% Nov/13

Indexes Price Day Year Date
USND 25136 -229.82 -0.91% 9.76% Nov/13

BioMarin Pharmaceutical traded at $57.23 this Friday November 13th, increasing $0.53 or 0.93 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical gained 3.79 percent. Over the last 12 months, its price rose by 4.57 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 55.94 by the end of this quarter and at 52.25 in one year, according to Trading Economics global macro models projections and analysts expectations.

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.